GLUE
Income statement / Annual
Last year (2025), Monte Rosa Therapeutics Inc's total revenue was $123.67 M,
an increase of 63.54% from the previous year.
In 2025, Monte Rosa Therapeutics Inc's net income was -$38.63 M.
See Monte Rosa Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$123.67 M |
$75.62 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$8.36 M
|
$8.12 M
|
$6.22 M
|
$0.00
|
$0.00
|
$537.00 K
|
$72.00 K
|
| Gross Profit |
$115.32 M
|
$67.50 M
|
-$6.22 M
|
$0.00
|
$0.00
|
-$537.00 K
|
-$72.00 K
|
| Gross Profit Ratio |
0.93
|
0.89
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$141.50 M
|
$121.56 M
|
$105.05 M
|
$85.06 M
|
$57.16 M
|
$23.47 M
|
$7.35 M
|
| General & Administrative Expenses |
$36.38 M
|
$35.17 M
|
$32.04 M
|
$27.32 M
|
$15.73 M
|
$4.01 M
|
$644.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$36.38 M
|
$35.17 M
|
$32.04 M
|
$27.32 M
|
$15.73 M
|
$4.01 M
|
$644.00 K
|
| Other Expenses |
-$8.36 M
|
-$8.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$169.52 M
|
$148.61 M
|
$137.09 M
|
$112.38 M
|
$72.88 M
|
$27.47 M
|
$7.99 M
|
| Cost And Expenses |
$177.88 M
|
$156.73 M
|
$143.31 M
|
$112.38 M
|
$72.88 M
|
$28.01 M
|
$7.99 M
|
| Interest Income |
$12.94 M
|
$10.57 M
|
$9.33 M
|
$3.76 M
|
$46.00 K
|
$9.00 K
|
$12.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$3.76 M
|
$0.00
|
$0.00
|
$1.00 K
|
| Depreciation & Amortization |
$8.36 M
|
$8.12 M
|
$6.22 M
|
$3.75 M
|
$2.13 M
|
$537.00 K
|
$72.00 K
|
| EBITDA |
-$45.85 M |
-$72.99 M |
-$137.09 M |
-$108.64 M |
-$70.75 M |
-$27.47 M |
-$7.67 M |
| EBITDA Ratio |
-0.37
|
-0.97
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.44
|
-1.07
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$14.49 M
|
$10.98 M
|
$8.30 M
|
$3.88 M
|
-$1.08 M
|
-$7.87 M
|
$254.00 K
|
| Income Before Tax |
-$39.72 M
|
-$70.13 M
|
-$135.01 M
|
-$108.50 M
|
-$73.96 M
|
-$35.88 M
|
-$7.74 M
|
| Income Before Tax Ratio |
-0.32
|
-0.93
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.10 M
|
$2.57 M
|
$338.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$38.63 M
|
-$72.70 M
|
-$135.35 M
|
-$108.50 M
|
-$73.96 M
|
-$35.88 M
|
-$8.02 M
|
| Net Income Ratio |
-0.31
|
-0.96
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.46 |
-0.98 |
-2.63 |
-2.3 |
-1.59 |
-0.82 |
-0.18 |
| EPS Diluted |
-0.46 |
-0.98 |
-2.63 |
-2.3 |
-1.59 |
-0.82 |
-0.18 |
| Weighted Average Shares Out |
$83.07 M
|
$73.91 M
|
$51.40 M
|
$47.23 M
|
$46.54 M
|
$44.00 M
|
$44.00 M
|
| Weighted Average Shares Out Diluted |
$83.07 M
|
$73.91 M
|
$51.40 M
|
$47.23 M
|
$46.54 M
|
$44.00 M
|
$44.00 M
|
| Link |
|
|
|
|
|
|
|
